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In their comment, González-Ortiz et al. cited their study that reported that in a 
randomized, doubleblind, placebo-controlled clinical trial of 12 overweight or obese 
male volunteers, of whom 6 received celecoxib for 4 weeks, the insulin sensitivity after 
celecoxib treatment was significantly higher compared with the basal estimation. Our 
study demonstrated that expression of cyclooxygenase- 2 (COX-2) in hepatocytes 
protects against adiposity, inflammation, and hepatic insulin resistance (IR) in mice fed 
a high-fat diet (HFD) and that DFU (a celecoxib analog) partially reversed the beneficial 
effects induced by COX-2– dependent prostaglandins. Contradictory results have been 
obtained in studies of transgenic mice and humans. COX-2–dependent prostaglandin 
E2 is considered a proin- flammatory mediator that is involved in the pathogenesis of 
several diseases. Inflammation induces the expression of COX-2; however, 
hepatocytes fail to induce COX-2 regardless of the proinflammatory stimuli used. Thus, 
ectopic expression of COX-2 in hepatocytes constitutes a nonphysiological condition 
ideal to conduct mechanistic studies to evaluate the role of prostaglandins in liver 
pathogenesis. Our previous results demonstrated reduced plasmatic levels of 
proinflammatory cytokines induced by lipopolysaccharide in COX-2 transgenic mice. 
These results agree with the data reported in our study in which decreased expression 
of proinflammatory cytokines in white fat revealed protection against low-grade chronic 
inflammation. In addition, COX-2–dependent prostaglandin E2, acting via EP2/EP4 
Gbg dimers, enhanced insulin signaling through Akt phosphorylation. Also, AMPK was 
phosphorylated in hepatocytes expressing COX-2 under the HFD condition, and this 
induced fatty acid oxidation contributing to the beneficial effects of COX-2 against 
obesity. Regarding the role of COX-2 inhibitors in the pathogenesis of obesity and IR, 
the results are controversial. Some studies reported that muscle and fat IR improved in 
rats fed HFD and treated with celecoxib. Others found that COX-2 inhibition 
exacerbated IR in skeletal muscle. Importantly, the concentrations of COX-2 inhibitors 
required to induce apoptosis are much higher than that required to inhibit COX-2 
activity, and these compounds also have antiproliferative effects in cells lacking COX-2. 
On the basis of these and other studies, it is assumed that the effects of COX-2 
inhibitors are mediated through both COX-2–dependent and –independent pathways. 
Hence, OSU- 03012, a non–cyclooxygenase-inhibiting celecoxib derivative, was used 
recently to induce apoptosis or to inhibit proliferation in different cells. Our results agree 
with Vegiopoulos et al., who reported that overexpression of COX-2 in adipose tissue 
induced browning, increased energy expenditure, and protected mice against obesity. 
Thus, the phenotype of two different models of COX-2 transgenic mice (adipose tissue 
and liver) exhibited the same behavior on obesity and insulin sensitivity. Finally, our 
recent publication went into depth on the mechanism by which COX-2 improves insulin 
signaling through the modulation of microRNA- 183 and IRS1. Regarding the clinical 
trial by González-Ortiz et al., it would be interesting to analyze the plasmatic levels of 
prostaglandins in these patients and the effect of celecoxib. We agree with González-
Ortiz et al. that more in-depth studies in humans should be performed in larger 
populations with longer interventions with different COX-2 inhibitors. 
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